Pharmacogenomics: Recent Advances in Personalized Therapy with Anticancer Drugs
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 312
Special Issue Editors
Interests: cancer pharmacogenetics and pharmacogenomics; personalized medicine; bioinformatics of pharmacogenomics; pharmacokinetic modeling; next-generation sequencing
Interests: pharmacogenetics/pharmacogenomics; oncology; clinical pharmacology; translational research; bioanalysis; pharmacokinetic/pharmacodynamic modeling
Special Issue Information
Dear Colleagues,
Pharmacogenomics (PGx)-guided dosing of anticancer drugs is one of the advanced approaches to personalizing cancer therapy, which is expected to improve drug safety and efficacy. For several anticancer drugs (e.g., fluoropyrimidines, irinotecan, and thiopurines), the concept of PGx-guided dosing has already shown its clinical value by reducing interpatient variability in pharmacokinetics (PK) and by reducing the risk of life-threatening toxicities.
With this background, the aim of this Special Issue is to showcase recent scientific advancements in the field of PGx to further improve cancer therapy. Relevant papers may cover the entire field of study, including the discovery of novel genomic variants as predictive biomarkers for toxicity, the development of innovative in vitro models utilizing state-of-the-art genetic manipulation and genome editing technologies, PGx-guided strategies for targeted therapies and immuno-oncology agents, and the use pharmacometric modeling and simulation to formulate novel PGx-guided dosing strategies.
We invite experts in the field to submit original research papers and review articles to this Special Issue.
Dr. Alireza Tafazoli
Dr. Andrew Goey
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacogenomics of anticancer drugs
- pharmacometrics
- pharmaceutical biotechnology for anticancer drugs
- in vitro drug metabolism/transporter dodels
- genome editing
- oncology
- germline polymorphisms
- next-generation sequencing
